Oncology Institute (NasdaqCM:TOI) - Share price, News & Analysis

TOI fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

TOI Stock Overview

The Oncology Institute, Inc., an oncology company, provides medical oncology services in the United States.

Rewards

Earnings have grown 7.8% per year over the past 5 years

Risk Analysis

Shareholders have been substantially diluted in the past year

Volatile share price over the past 3 months

Oncology Institute Competitors

Pennant Group

NasdaqGS:PNTG

US$516.3m

Hanger

NYSE:HNGR

US$727.3m

Joint

NasdaqCM:JYNT

US$325.8m

National HealthCare

NYSEAM:NHC

US$1.1b

Price History & Performance

Summary of all time highs, changes and price drops for Oncology Institute
Historical stock prices
Current Share Price	US$6.51
52 Week High	US$12.66
52 Week Low	US$3.75
Beta	1.78
1 Month Change	21.00%
3 Month Change	6.37%
1 Year Change	-34.51%
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	-32.89%

Shareholder Returns

	TOI	US Healthcare	US Market
7D	-1.5%	1.0%	1.3%
1Y	-34.5%	15.6%	-11.7%

Return vs Industry: TOI underperformed the US Healthcare industry which returned 15.6% over the past year.

Return vs Market: TOI underperformed the US Market which returned -11.7% over the past year.

Price Volatility

Is TOI's price volatile compared to industry and market?
TOI volatility
TOI Average Weekly Movement	13.0%
Healthcare Industry Average Movement	8.9%
Market Average Movement	7.8%
10% most volatile stocks in US Market	16.9%
10% least volatile stocks in US Market	3.2%

Stable Share Price: TOI is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 13% a week.

Volatility Over Time: TOI's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

Founded	Employees	CEO	Website
2007	658	Brad Hively	https://theoncologyinstitute.com

The Oncology Institute, Inc., an oncology company, provides medical oncology services in the United States. Its services include physician services, in-house infusion and dispensary, clinical trial services, radiation, outpatient stem cell transplants and transfusions programs, and patient support. The company also offers and manages clinical trial services, such as managing clinical trials, palliative care programs, and stem cell transplants services.

Oncology Institute Fundamentals Summary

How do Oncology Institute's earnings and revenue compare to its market cap?
TOI fundamental statistics
Market Cap	US$469.63m
Earnings (TTM)	-US$1.89m
Revenue (TTM)	US$220.66m

2.1x

P/S Ratio

-248.8x

P/E Ratio

Is TOI overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report
TOI income statement (TTM)
Revenue	US$220.66m
Cost of Revenue	US$177.44m
Gross Profit	US$43.22m
Other Expenses	US$45.11m
Earnings	-US$1.89m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)	-0.026
Gross Margin	19.59%
Net Profit Margin	-0.86%
Debt/Equity Ratio	0%

How did TOI perform over the long term?

See historical performance and comparison

We’ve recently updated our valuation analysis.

Valuation

Is TOI undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for TOI?

Other financial metrics that can be useful for relative valuation.

The above table shows the n/a ratio for TOI. This is calculated by dividing TOI's market cap by their current preferred multiple.
What is TOI's n/a Ratio?
n/a Ratio	0x
n/a	n/a
Market Cap	US$469.63m

TOI key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	1.9x
Enterprise Value/EBITDA	-5.7x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does TOI's PS Ratio compare to its peers?

TOI PS Ratio vs Peers

The above table shows the PS ratio for TOI vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	PS	Estimated Growth	Market Cap
Peer Average	1.6x
PNTG Pennant Group	1.1x	7.3%	US$516.3m
HNGR Hanger	0.6x	4.7%	US$727.3m
JYNT Joint	3.6x	17.7%	US$325.8m
NHC National HealthCare	1x	n/a	US$1.1b
TOI Oncology Institute	2.1x	n/a	US$469.6m

Price-To-Sales vs Peers: TOI is expensive based on its Price-To-Sales Ratio (2.1x) compared to the peer average (1.6x).

Price to Earnings Ratio vs Industry

How does TOI's PE Ratio compare vs other companies in the US Healthcare Industry?

Price-To-Sales vs Industry: TOI is expensive based on its Price-To-Sales Ratio (2.1x) compared to the US Healthcare industry average (1.5x)

Price to Sales Ratio vs Fair Ratio

What is TOI's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

TOI PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	2.1x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate TOI's Price-To-Sales Fair Ratio for valuation analysis.

Share Price vs Fair Value

What is the Fair Price of TOI when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate TOI's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate TOI's fair value for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Future Growth

How is Oncology Institute forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

Future Growth Score

0/6

Future Growth Score 0/6

Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE

13.0%

Forecasted Healthcare industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Oncology Institute has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Discover growth companies

Examine Oncology Institute's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.

Past Performance

How has Oncology Institute performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE

7.8%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: TOI is currently unprofitable.

Growing Profit Margin: TOI is currently unprofitable.

Past Earnings Growth Analysis

Earnings Trend: TOI is unprofitable, but has reduced losses over the past 5 years at a rate of 7.8% per year.

Accelerating Growth: Unable to compare TOI's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: TOI is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare industry (8.1%).

Return on Equity

High ROE: TOI has a negative Return on Equity (0.56%), as it is currently unprofitable.

Discover strong past performing companies

Financial Health

How is Oncology Institute's financial position?

Financial Health Score

6/6

Financial Health Score 6/6

Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Stable Cash Runway
Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: TOI's short term assets ($112.2M) exceed its short term liabilities ($36.1M).

Long Term Liabilities: TOI's short term assets ($112.2M) exceed its long term liabilities ($29.6M).

Debt to Equity History and Analysis

Debt Level: TOI is debt free.

Reducing Debt: TOI had no debt 5 years ago.

Balance Sheet

Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: TOI has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: TOI is forecast to have sufficient cash runway for 8 months based on free cash flow estimates, but has since raised additional capital.

Discover healthy companies

Dividend

What is Oncology Institute current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Cash Flow Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate TOI's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate TOI's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if TOI's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if TOI's dividend payments have been increasing.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as TOI has not reported any payouts.

Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

0.6yrs

Average management tenure

CEO

Brad Hively

0.75

Tenure

US$11,635,535

Compensation

Mr. Bradford D. Hively, also known as Brad, serves as Strategic Advisors at Riordan, Lewis & Haden. Mr. Hively previously served as an Operating Professional at the firm. He serves as Chief Executive Offic...

CEO Compensation Analysis

Compensation vs Market: Brad's total compensation ($USD11.64M) is above average for companies of similar size in the US market ($USD2.57M).

Compensation vs Earnings: Brad's compensation has increased whilst the company is unprofitable.

Leadership Team

Experienced Management: TOI's management team is not considered experienced ( 0.6 years average tenure), which suggests a new team.

Board Members

Experienced Board: TOI's board of directors are not considered experienced ( 0.8 years average tenure), which suggests a new board.

Ownership

Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 150.9%.

Data	Last Updated (UTC time)
Company Analysis	2022/08/12 00:00
End of Day Share Price	2022/08/12 00:00
Earnings	2022/06/30
Annual Earnings	2021/12/31